Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза IV Россия

Fluticasone propionate; Fluticasone propionate/salmeterol

A Multicentre, Randomised, Double-blind, Double Dummy, Parallel Group Study to Compare the Salmeterol/Fluticasone Propionate Combination (SeretideTM) at a Dose of 50/100µg Twice Daily and Fluticasone Propionate (FlixotideTM) at a Dose of 200µg Twice Daily, Both Delivered Via a Dry Powder Inhaler (DiskusTM) for 12 Weeks in Asthma in Children Aged 4-11 Years Not Controlled by Inhaled Corticosteroids Alone at Medium Dose

Номер протоколаSAM104926
ФазаФаза IV
Участников по плану — во всех странах исследования506
Сроки18.11.2005 — 26.10.2006
Начало: 18 ноября 2005Окончание: 26 октября 2006
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00353873/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 4–11 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 506 чел. во всех странах исследования.
  • Плановая дата окончания (10.2006) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст4–11 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 18

Критерии включения

  • A documented clinical history of asthma for a period of at least 6 months.
  • A documented history (within 12 months of Visit 1) of airway reversibility of = 15% based either on Forced expiratory volume (FEV1) or PEF measured pre and post inhalation of 200 mcg salbutamol. (If no documented history of reversibility exists, patients must demonstrate a =15% reversibility at Visit 1).
  • Receiving an inhaled corticosteroid at a medium dose (beclomethasone dipropionate HydroFluoroAlkane (HFA) non fine particle = 400-500 mcg/day or beclomethasone HFA fine particle = 200mcg/day, or budesonide =400 mcg/day or fluticasone = 200 mcg/day (or fluticasone 250mcg/day if subject is taking a 125mcg MDI rather than the 100mcg Diskus), for at least 3 months prior to Visit 1 and at a stable dose for at least 4 weeks prior to Visit 1.
  • Able to use the Mini-Wright peak flow meter and subject or parent/guardian had to be able to record the subject's maximum PEF correctly.
  • Able to perform FEV1 correctly.
  • Subject's guardian/parent able to complete an eDRC on behalf of the subject. The eDRC should be completed by the guardian/parent.
  • Able to use a DISKUS™ correctly.
  • At least one parent(s)/guardian(s) has to give written informed consent to participate in the study.
  • At the end of the run-in period (Visit 2), subjects must still meet the criteria for entry into the run-in period and also have:
  • not achieved the criteria for the 'Well-controlled' asthma during two or more of the 4 weeks prior to Visit 2.

Критерии невключения

  • Female subjects who have reached menarche.
  • Received any investigational study medication in the 4 weeks prior to Visit 1.
  • Experienced a respiratory tract infection in the 4 weeks prior to Visit 1.
  • Experienced an acute asthma exacerbation requiring emergency room treatment within 4 weeks or hospitalisation within 12 weeks of Visit 1.
  • Any use of oral/parenteral or depot corticosteroid within 12 weeks of Visit 1.
  • Any use of long-acting inhaled beta2-agonists or oral beta2-agonists within 4 weeks of Visit 1.
  • Any use of leukotriene antagonists or theophyllines within 4 weeks of Visit 1.
  • Any known clinical or laboratory evidence of a serious uncontrolled disease (including serious psychological disorders) which is, in the opinion of the investigator, likely to interfere with the study.
  • Subjects with a known or suspected hypersensitivity to inhaled corticosteroids, beta2-agonists, or any components of the formulations (e.g. lactose)
  • A relative of any of the site staff, including the investigator or study co-coordinator.
  • Has previously been entered into this study.
  • Subjects will be excluded from participating in the treatment period of the study if the following occurred during the run-in period:
  • Pre-bronchodilator FEV1 <60% (assuming that measurement was correctly performed).
  • Any change in asthma medication (excluding use of prophylactic study specific salbutamol for prevention of asthma symptoms due to exercise).
  • Respiratory tract infection or asthma exacerbation.
  • Use of oral, parenteral or depot corticosteroids.
  • Emergency visit due to asthma.
  • Non-compliance with the completion of the eDRC (i.e. during the 4 week period between visits, non compliance is defined as less than 5 days of completed data within any one week for four weeks - subjects must complete at least 5 days a week for the entire run-in period).

Источник: ClinicalTrials.gov, NCT00353873 · запись обновлена в реестре 29 мая 2018.

Дизайн и результаты

ДизайнРандомизированное, двойное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)506
Что измеряют — первичные конечные точки (2), вторичных — 2
  • Mean Change From Baseline in Morning Peak Expiratory Flow (PEF) Over 12 Weeks in Intent-to-treat (ITT) Population — Baseline; Week 1 up to Week 12
  • Mean Change From Baseline in Morning PEF Over 12 Weeks in Per Protocol (PP) Population — Baseline; Week 1 up to Week 12

Цель исследования

This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium dose. The fixed combination SERETIDE 100/50 one inhalation twice daily will be compared to FLIXOTIDE 100 two inhalations twice daily.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00353873 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.